Plasma magnesium and the risk of new-onset hyperuricaemia in hypertensive patients

We aimed to evaluate the relationship of plasma Mg with the risk of new-onset hyperuricaemia and examine any possible effect modifiers in hypertensive patients. This is apost hocanalysis of the Uric acid (UA) Sub-study of the China Stroke Primary Prevention Trial (CSPPT). A total of 1685 participants were included in the present study. The main outcome was new-onset hyperuricaemia defined as a UA concentration >= 417 mu mol/l in men or >= 357 mu mol/l in women. The secondary outcome was a change in UA concentration defined as UA at the exit visit minus that at baseline. During a median follow-up duration of 4 center dot 3 years, new-onset hyperuricaemia occurred in 290 (17 center dot 2 %) participants. There was a significantly inverse relation of plasma Mg with the risk of new-onset hyperuricaemia (persdincrement; OR 0 center dot 85; 95 % CI 0 center dot 74, 0 center dot 99) and change in UA levels (persdincrement;beta-3 center dot 96 mu mol/l; 95 % CI -7 center dot 14, -0 center dot 79). Consistently, when plasma Mg was analysed as tertiles, a significantly lower risk of new-onset hyperuricaemia (OR 0 center dot 67; 95 % CI 0 center dot 48, 0 center dot 95) and less increase in UA levels (beta-8 center dot 35 mu mol/l; 95 % CI -16 center dot 12, -0 center dot 58) were found among participants in tertile 3 (>= 885 center dot 5 mu mol/l) compared with those in tertile 1 (<818 center dot 9 mu mol/l). Similar trends were found in males and females. Higher plasma Mg levels were associated with a decreased risk of new-onset hyperuricaemia in hypertensive adults.